Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPennsylvania Department of Human ServicesPennsylvania DHS Brineura Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPennsylvania Department of Human ServicesPolicy N/A

    Prior Authorization of Brineura (cerliponase alfa) - Pharmacy Services

    Customize your policy alerts

    Sign up for all Pennsylvania Department of Human Services policy alerts

    Know when Pennsylvania Department of Human Services releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization requirements and medical-necessity review for Brineura prescriptions in Pennsylvania Medical Assistance fee-for-service. It applies to enrolled prescribers and licensed pharmacies, including providers serving residents of long-term care facilities.

    Policy Summary
    PayerPennsylvania Department of Human Services
    PolicyPrior Authorization of Brineura (cerliponase alfa) - Pharmacy Services
    Policy CodePolicy N/A
    Change TypeNew policy implementation
    Effective DateJanuary 8, 2018
    Next Review DateN/A
    Key ActionObtain prior authorization for every Brineura prescription.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    AllPrescriptions requiring prior authorization
    3+Minimum beneficiary age
    6 monthsInitial approval period
    12 monthsRenewal approval period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    7Standard initial criteria
    6Standard renewal criteria

    Coverage Criteria

    Initial Therapy Criteria

    Covered when all standard initial criteria are met, or when a physician reviewer determines that the services are medically necessary despite the standard criteria not being met.

    Initial therapy medical necessity

    • Standard initial criteria

      • Confirmed CLN2 diagnosis: The beneficiary is being treated for late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), documented by deficient tripeptidyl peptidase 1 (TPP1) enzyme activity or mutations in the CLN2/TPP1 gene.
      • Age requirement: The beneficiary is 3 years of age or older.>= 3 years
      • Baseline clinical rating: A baseline CLN2 Clinical Rating Scale score is documented.Baseline score documented
      • Specialist involvement: Brineura is prescribed by or in consultation with a pediatric neurologist.
      • Dose consistent with labeling: The prescribed dose is consistent with FDA-approved package labeling for the diagnosis.FDA-approved package labeling
      • Administration consistent with labeling: Brineura will be administered in accordance with FDA-approved package labeling.FDA-approved package labeling
      • No contraindication: The beneficiary does not have a contraindication to Brineura.
    • Physician-reviewer exception: The standard clinical review guidelines are not met, but the physician reviewer determines that the services are medically necessary to meet the medical needs of the beneficiary.Physician reviewer medical-necessity determination

    Renewal Therapy Criteria

    Covered renewal requests when all standard renewal criteria are met, or when a physician reviewer determines that the services are medically necessary despite the standard criteria not being met.

    Renewal medical necessity

    • Standard renewal criteria

      • Specialist involvement: Brineura is prescribed by or in consultation with a pediatric neurologist.
      • Repeat clinical rating: A repeat CLN2 Clinical Rating Scale score is documented.Repeat score documented
      • Continued benefit: Based on the prescriber's professional judgment, the beneficiary continues to benefit from Brineura.Prescriber judgment of continued benefit

    A beneficiary with a contraindication to Brineura (cerliponase alfa) does not meet the standard initial or renewal coverage criteria.

    Age Requirement

    Minimum age
    Minimum age3 years or older
    Applies toStandard initial-therapy criteria
    Related requirementThe beneficiary must also have documented CLN2 and a baseline CLN2 Clinical Rating Scale score

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required for Every Prescription

    Every prescription for Brineura (cerliponase alfa) requires prior authorization. DHS reviews the submitted information to determine whether the prescription is medically necessary.

    • Submit a prior-authorization request for every Brineura prescription, including initial prescriptions and renewals.
    Prior Authorization

    Use Handbook Prior-Authorization Procedures

    Follow the procedures in Section I of the Prior Authorization of Pharmaceutical Services Handbook when requesting prior authorization for Brineura. DHS will apply the clinical review guidelines in the Section II Brineura chapter when evaluating medical necessity, and the handbook procedures must be followed for appropriate and timely processing under 55 Pa. Code § 1101.67(a).

    • Direct prescribers to Section I of the Prior Authorization of Pharmaceutical Services Handbook.
    • Review the Section II Brineura clinical review guidelines before submitting the request.

    Clinical Definitions

    CLN2
    Full nameLate infantile neuronal ceroid lipofuscinosis type 2
    Enzyme evidenceDeficient tripeptidyl peptidase 1 (TPP1) enzyme activity
    Genetic evidenceMutations in the CLN2/TPP1 gene
    CLN2 Clinical Rating Scale score
    Initial therapyA baseline CLN2 Clinical Rating Scale score must be documented
    Renewal therapyA repeat CLN2 Clinical Rating Scale score must be documented
    PurposeThe score is the clinical rating measure used to support initial and renewal requests

    Initial Therapy

    Initial Therapy Criteria

    Initial requests are evaluated against seven standard criteria, with an alternative physician-reviewer medical-necessity pathway.

    Initial therapy medical necessity

    • Seven standard initial criteria

      • The beneficiary is being treated for late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), documented by deficient tripeptidyl peptidase 1 (TPP1) enzyme activity or mutations in the CLN2/TPP1 gene.
      • The beneficiary is 3 years of age or older.>= 3 years
      • A baseline CLN2 Clinical Rating Scale score is documented.Baseline score documented

    Renewal of Previously Approved Therapy

    Renewal of Previously Approved Therapy

    Renewal requests for previously approved Brineura prescriptions are evaluated against the continuation criteria below, or may be approved through physician-reviewer medical-necessity determination.

    Renewal medical necessity

    • Renewal criteria

      • Brineura (cerliponase alfa) is prescribed by or in consultation with a pediatric neurologist.
      • A repeat CLN2 Clinical Rating Scale score is documented.Repeat score documented
      • Based on the prescriber's professional judgment, the beneficiary continues to benefit from Brineura (cerliponase alfa).Prescriber judgment of continued benefit

    Approval Periods

    Approval period
    DrugBrineura (cerliponase alfa)
    Initial prescriptionApproval for a period of up to six (6) months
    Previously approved renewalApproval for a period of up to 12 months
    Policy Summary
    PayerPennsylvania Department of Human Services
    PolicyPrior Authorization of Brineura (cerliponase alfa) - Pharmacy Services
    Policy CodePolicy N/A
    Change TypeNew policy implementation
    Effective DateJanuary 8, 2018
    Next Review DateN/A
    Key ActionObtain prior authorization for every Brineura prescription.
    SourceLink
    On This Page
    Coverage CriteriaAge RequirementPrior Authorization and DocumentationClinical DefinitionsInitial TherapyRenewal of Previously Approved TherapyApproval Periods
  1. Dose consistent with labeling: The prescribed dose is consistent with FDA-approved package labeling for the diagnosis.FDA-approved package labeling
  2. Administration consistent with labeling: Brineura will be administered in accordance with FDA-approved package labeling.FDA-approved package labeling
  3. No contraindication: The beneficiary does not have a contraindication to Brineura.
  4. Physician-reviewer exception: The standard clinical review guidelines are not met, but the physician reviewer determines that the services are medically necessary to meet the medical needs of the beneficiary.Physician reviewer medical-necessity determination
  5. Documentation Required

    Initial Clinical Documentation Required

    Include documentation showing that the beneficiary meets the initial medical-necessity requirements for Brineura. The request must address each applicable clinical, prescribing, administration, and safety requirement.

    • Diagnosis of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), documented by deficient tripeptidyl peptidase 1 (TPP1) enzyme activity or mutations in the CLN2/TPP1 gene.
    • Beneficiary is 3 years of age or older.
    • Baseline CLN2 Clinical Rating Scale score is documented.
    • Brineura is prescribed by or in consultation with a pediatric neurologist.
    • Dose is consistent with FDA-approved package labeling for the diagnosis.
    • Administration will follow FDA-approved package labeling.
    • Beneficiary does not have a contraindication to Brineura.
    Documentation Required

    Renewal Clinical Documentation Required

    For renewal requests previously approved by DHS, document continued clinical eligibility and benefit from Brineura. Renewal documentation must support each renewal requirement.

    • Brineura is prescribed by or in consultation with a pediatric neurologist.
    • A repeat CLN2 Clinical Rating Scale score is documented.
    • The prescriber’s professional judgment supports that the beneficiary continues to benefit from Brineura.
    • Dose is consistent with FDA-approved package labeling for the diagnosis.
    • Administration will follow FDA-approved package labeling.
    • Beneficiary does not have a contraindication to Brineura.
    Denial Risk

    Failure to Meet Clinical Criteria

    A request may be denied when the beneficiary does not satisfy the standard initial medical-necessity criteria or when the submitted documentation is incomplete. The standard criteria require all listed clinical, age, prescribing, dosing, administration, and safety requirements; however, a physician reviewer may determine that services are medically necessary based on professional judgment even when the clinical review guidelines are not met.

    • CLN2 diagnosis is not documented through deficient TPP1 enzyme activity or CLN2/TPP1 gene mutations.
    • Beneficiary is younger than 3 years of age.
    • Baseline CLN2 Clinical Rating Scale score is missing.
    • Pediatric-neurologist involvement is not documented.
    • Dose or administration is inconsistent with FDA-approved package labeling.
    • A contraindication to Brineura is present.
    • The physician reviewer does not determine, based on professional judgment, that the services are medically necessary despite failure to meet the clinical review guidelines.
    Denial Risk

    Renewal Criteria Not Met

    A renewal request may be denied if any renewal requirement is not met or is not supported by documentation. Continued approval requires pediatric-neurologist involvement, a repeat clinical rating score, continued benefit, appropriate dosing and administration, and no contraindication.

    • Brineura is not prescribed by or in consultation with a pediatric neurologist.
    • Repeat CLN2 Clinical Rating Scale score is not documented.
    • The prescriber does not support that the beneficiary continues to benefit from Brineura.
    • Dose or administration is inconsistent with FDA-approved package labeling.
    • A contraindication to Brineura is present.
  6. Brineura (cerliponase alfa) is prescribed by or in consultation with a pediatric neurologist.
  7. The prescribed dose is consistent with FDA-approved package labeling for the diagnosis.FDA-approved package labeling
  8. Brineura (cerliponase alfa) will be administered in accordance with FDA-approved package labeling.FDA-approved package labeling
  9. The beneficiary does not have a contraindication to Brineura (cerliponase alfa).
  10. Alternative physician-reviewer pathway: The beneficiary does not meet the standard clinical review guidelines, but in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.Physician reviewer medical-necessity determination
  11. The prescribed dose is consistent with FDA-approved package labeling for the diagnosis.FDA-approved package labeling
  12. Brineura (cerliponase alfa) will be administered in accordance with FDA-approved package labeling.FDA-approved package labeling
  13. The beneficiary does not have a contraindication to Brineura (cerliponase alfa).
  14. Alternative physician-reviewer pathway: The beneficiary does not meet the standard clinical review guidelines, but in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.Physician reviewer medical-necessity determination